119, my comment was sort of tongue in cheek as well. Transmeta deserved that win, and they came out with an excellent product. I have simply been frustrated that such a high profile and successful design did not translate into TMTA's bottom line. Last quarter was abysmal, and Dr. Perry's slip in the profitability forecast only proved to me that this dog won't hunt. Sorry for the harsh words, but I couldn't bring myself to invest in TMTA again.